https://www.appliedxl.com/news/first-affiliated-hospital-zhejiang-university-school-nct05155189 Biopharma News en 2026-07-23T14:24:59.230Z AstraZeneca's GPC3 CAR-T shows 44% response rate in liver cancer, Nature reports https://www.appliedxl.com/news/johnson-tecvayli-talvey-teclistamab-cqyv-talquetamab-tgvs-nct06208150 Biopharma News en 2026-07-23T12:45:30.961Z J&J's Tecvayli-Talvey combo cuts myeloma progression risk 89% in Phase 3 https://www.appliedxl.com/news/lantern-184-2024-readout-nct05933265-96a8c5 Biopharma News en 2026-07-23T12:25:51.612Z Lantern Pharma's LP-184 hits 45% disease control rate in Phase 1a tumor trial https://www.appliedxl.com/news/felzartamab-antibody-mediated-rejection-amr-kidney-nct05021484 Biopharma News en 2026-07-23T12:15:14.092Z dd-cfDNA guidance cut felzartamab dosing by two-thirds in kidney rejection https://www.appliedxl.com/news/eli-lilly-retatrutide-2026-readout-nct05882045 Biopharma News en 2026-07-23T11:06:46.185Z Lilly's retatrutide cuts weight 22.6% in cardiovascular-disease patients https://www.appliedxl.com/news/eli-lilly-retatrutide-2026-readout-nct05929079 Biopharma News en 2026-07-23T11:05:22.366Z Lilly's retatrutide hits 20.8% weight loss, 1.6% A1C cut in TRIUMPH-2 https://www.appliedxl.com/news/koya-dayspring-2026-readout-nct05507346 Biopharma News en 2026-07-23T10:15:03.621Z Koya's Dayspring beats pneumatic compression in older, phlebolymphedema patients https://www.appliedxl.com/news/koya-dayspring-2026-readout-nct05507346-7565a2 Biopharma News en 2026-07-23T11:24:54.425Z Koya's Dayspring beats pneumatic device in TEAYS lymphedema subgroups https://www.appliedxl.com/news/surabgene-lomparvovec-sura-vec-abbv-rgx-314-wet-age-related-macular Biopharma News en 2026-07-23T00:05:24.556Z AbbVie's ASCENT gene-therapy trial vs. aflibercept in wet AMD nears Q4 2026 data https://www.appliedxl.com/news/clostrabio-anaerostipes-caccae-clb101-2026-readout-nct07336615 Biopharma News en 2026-07-22T13:25:06.432Z ClostraBio says probiotic CLB101 hit safety goal, but posts no numbers https://www.appliedxl.com/news/ucsf-rb-pdat-2026-readout-nct05110001 Biopharma News en 2026-07-22T12:15:00.978Z UCSF's REAGIR trial misses primary endpoint for Rose Bengal eye therapy https://www.appliedxl.com/news/plozasiran-severe-hypertriglyceridemia-readout-2026-c614e3-nct06347003 Biopharma News en 2026-07-22T11:45:34.875Z Arrowhead's plozasiran cuts triglycerides 79% and pancreatitis events in Phase 3 https://www.appliedxl.com/news/plozasiran-severe-hypertriglyceridemia-readout-2026-nct06347016 Biopharma News en 2026-07-22T11:45:09.865Z Arrowhead's plozasiran cuts triglycerides 81% in Phase 3 SHASTA-4 https://www.appliedxl.com/news/radiopharm-theranostics-rad-204-2026-readout-nct06305962 Biopharma News en 2026-07-22T11:26:07.947Z Radiopharm's RAD204 shows one durable partial response in dose-escalation cohort https://www.appliedxl.com/news/emavusertib-ca-4948-relapsed-refractory-primary-central-nct03328078 Biopharma News en 2026-07-22T11:15:43.917Z Curis's emavusertib shows responses in BTKi-resistant brain lymphoma, no ORR given https://www.appliedxl.com/news/science-prima-2026-readout-nct04676854 Biopharma News en 2026-07-22T10:15:33.961Z Science Corp's PRIMA implant restores reading vision in geographic atrophy trial https://www.appliedxl.com/news/deramiocel-duchenne-muscular-dystrophy-dmd-cardiomyopathy-fda Biopharma News en 2026-07-22T00:05:16.902Z Capricor's deramiocel faces Aug. 22 FDA decision after CRL reversal https://www.appliedxl.com/news/telix-tlx591-tx-lutetium-177-177lu-rosopatamab-tetraxetan-nct04786847 Biopharma News en 2026-07-21T21:16:04.194Z Telix's TLX591-Tx posts 8.8-month rPFS in small Phase 1 mCRPC study https://www.appliedxl.com/news/acrivon-acr-2316-2026-data-nct06667141 Biopharma News en 2026-07-21T20:46:40.772Z Acrivon presents early ACR-2316 partial responses in WEE1-resistant tumor types https://www.appliedxl.com/news/barzolvolimab-prurigo-nodularis-pn-readout-2026-nct06366750 Biopharma News en 2026-07-21T20:16:27.302Z Celldex's barzolvolimab fails Phase 2 prurigo nodularis trial despite mast cell wipeout